Quarterly ResultMay 11, 2026, 04:20 PM
Eikon Therapeutics Completes IPO, Reports Q1 Net Loss of $83.0M
AI Summary
Eikon Therapeutics completed its initial public offering on February 6, 2026, raising approximately $348.1 million in net proceeds and converting all preferred stock into common stock, significantly improving its equity position. For the first quarter ended March 31, 2026, the company reported a net loss of $83.0 million, an increase from $68.2 million in the prior year. Despite the loss, Eikon believes its $596.0 million in cash, cash equivalents, and marketable securities will provide sufficient liquidity for at least one year.
Key Highlights
- Eikon Therapeutics completed IPO on Feb 6, 2026, raising $348.1M net.
- Issued 21,177,600 common shares at $18.00 per share in IPO.
- All preferred stock converted to 29,855,741 common shares.
- Reported Q1 2026 net loss of $83.0M, up from $68.2M in Q1 2025.
- Q1 2026 R&D expenses increased to $70.0M from $56.6M YoY.
- Cash, equivalents, marketable securities totaled $596.0M as of March 31, 2026.
- Stockholders' equity shifted to $550.7M from $(879.0M) deficit.
- Effected 1-for-7.4578 reverse stock split on January 27, 2026.